One month ago, we started this fight for affordable access to GLP-1 medications. Together, we’ve achieved so much in such a short time: over 14,000 signatures, more than $1,000 raised to amplify our message, three media interviews, and dozens of powerful stories shared by advocates like you.

Today, we took another critical step forward. For the second time, we’ve contacted the FDA to demand action. Tomorrow, they will decide whether Tirzepatide remains on the shortage list—a decision that could drastically limit access to this life-changing medication for thousands of people who depend on it.

This fight isn’t just about tomorrow’s decision. It’s about securing permanent, affordable access to both Tirzepatide and Semaglutide—so that no one has to live in fear of losing the medication they need to reclaim their health. Whether it’s through keeping compounding options available, bringing down the price of brand-name medications, ensuring stable insurance coverage, or FDA-regulated generics, the goal is clear: lasting solutions, not temporary fixes.

Thank you to everyone who has stood with us in this fight. Together, we’ve already made waves, and we’re not stopping. We are taking steps every day to turn this goal into a reality.

Click here to read our email to the FDA and find out more about our efforts thus far.

Please continue to share the petition, spread the word, and raise your voice. This movement is growing stronger every day, thanks to you.

Let’s keep going—this is just the beginning! 💪